- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03055455
Neuroimaging and Neuromonitoring in Critically Ill Children With Sepsis
April 9, 2021 updated by: Children's Hospital of Philadelphia
In critically ill children with severe sepsis, neurophysiologic derangements often proceed undetected and can lead to irreversible brain injury causing neurocognitive and behavioral deficits.
The etiology of these impairments is unclear, however, it is likely that some of this neural injury is preventable.
The overarching goal for this study is to show that acute acquired structural and microstructural brain injury occurs in critically ill children with severe sepsis, and that this injury is related to neuropsychological deficits and impaired cerebral autoregulation (CAR).
Subjects will complete Magnetic resonance (MR) imaging within 2-10 days of recognition of their severe sepsis.
Subjects will undergo serial interrogation of CAR for up to 10 days.
CAR will be determined by the correlation of arterial blood pressure with middle cerebral artery flow velocity measured by transcranial doppler ultrasonography and cerebral oximetry derived from near-infrared spectroscopy.
Subjects will also participate in a neuropsychological evaluation 6 months after enrollment to evaluate multiple domains of behavior and cognition.
Study Overview
Study Type
Observational
Enrollment (Actual)
8
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- The Children's Hospital of Philadelphia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Children admitted to the pediatric intensive care unit (PICU) at the Children's Hospital of Philadelphia (CHOP) with severe sepsis from an extracranial source and have no history of a preexisting underlying a neurologic disorder.
Description
Inclusion Criteria:
- Admission to the Children's Hospital of Philadelphia (CHOP) pediatric intensive care unit (PICU)
- Males or females ages ≥ 3.5 years and ≤ 18 years on day of sepsis recognition
- Meet published consensus criteria for severe sepsis or septic shock: a) ≥ 2 systemic inflammatory response syndrome criteria, b) suspected (based on attending physician) or confirmed systemic infection, and c) ≥ 2 or more organ system dysfunctions (severe sepsis) or cardiovascular dysfunction (septic shock).
- An indwelling arterial catheter.
- Parental/guardian permission (informed consent).
- The patient and parent/guardian are fluent in English.
Exclusion Criteria:
- History of neurologic disorder including (hypoxic ischemic injury, traumatic brain injury, epileptic encephalopathy, neurodevelopmental, neurometabolic or neurogenetic conditions, and structural brain anomalies).
- History of cancer or undergoing treatment for cancer.
- Meningitis or encephalitis as source of sepsis.
- Congenital heart disease.
- History of cardiac arrest.
- History of extracorporeal membrane oxygenation (ECMO) cannulation.
- Patients with contraindications to MR scanning.
- Pregnant or lactating females.
- Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
- Previous enrollment in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Sepsis
Children with severe sepsis or septic shock
|
Conventional structural imaging will be combined with advanced neuroimaging modalities to evaluate integrity of white matter tracts, regional brain perfusion, and the 3-dimensional volume of specific brain structures.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRI
Time Frame: 2-10 days
|
Detection of signal abnormality on the patient's brain MRI scan.
|
2-10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CAR
Time Frame: Daily for 10 days
|
Trends in functionality of CAR over the first 10 days of severe sepsis.
Identification of the optimal blood pressure range where CAR is most functional.
|
Daily for 10 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Matthew Kirschen, MD, PhD, CHOP
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2017
Primary Completion (Actual)
September 27, 2019
Study Completion (Actual)
September 27, 2019
Study Registration Dates
First Submitted
February 14, 2017
First Submitted That Met QC Criteria
February 14, 2017
First Posted (Actual)
February 16, 2017
Study Record Updates
Last Update Posted (Actual)
April 12, 2021
Last Update Submitted That Met QC Criteria
April 9, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-012645
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Septic Shock
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, BonnUnknownSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockGermany
-
University Medicine GreifswaldUnknownSepsis Septic ShockGermany
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated...Recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedSeptic Shock HyperdynamicFrance
-
Centre Hospitalier Universitaire DijonCompleted
-
Mansoura UniversityUnknown
-
National Taiwan University HospitalBaxter Healthcare CorporationRecruiting
-
Charite University, Berlin, GermanyCompleted
-
University of ZurichCompletedPatients in Septic ShockSwitzerland
Clinical Trials on MR imaging
-
National Institute of Diabetes and Digestive and...RecruitingHealthy | Obesity | Diabetes | Atherosclerosis | Healthy VolunteersUnited States
-
University of NebraskaPhilips Medical SystemsTerminatedDiffuse and Focal Abnormalities of the Liver and PancreasUnited States
-
Stanford UniversityRecruiting
-
Stanford UniversityThe American Association of Physicists in MedicineTerminatedPancreatic Cancer | Lung Cancer | Liver Cancer | Hepatobiliary Cancers | Hepatobiliary Cancers Liver | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC) | Hepatobiliary Cancers Hepatocellular Carcinoma (Hepatoma) | Hepatobiliary Cancers Gallbladder | Hepatobiliary Cancers...United States
-
Cedars-Sinai Medical CenterRecruitingCoronary Artery Disease | CancerUnited States
-
Martin DichgansRecruitingCerebral Amyloid AngiopathyGermany
-
Manchester University NHS Foundation TrustCompletedNeurofibromatosis Type 2United Kingdom
-
Universitaire Ziekenhuizen KU LeuvenUnknownMalignant GliomasBelgium
-
Turku University HospitalCompletedBladder CancerFinland
-
University of ZurichCompletedNerve DegenerationSwitzerland